Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older
Latest Information Update: 28 Jan 2025
At a glance
- Drugs MRT 5407 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
Most Recent Events
- 03 Apr 2024 Status changed from active, no longer recruiting to completed.
- 31 May 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2022 Planned End Date changed from 12 Jan 2024 to 19 Jan 2024.